AbCellera Biologics Inc. cotiza a 12.16 USD y tiene una capitalización bursátil de $3.9B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.18 | $-0.14 | $-0.03 |
| Estimado | $-0.18 | $-0.16 | $-0.20 | $-0.18 |
| Sorpresa | — | -12.5% | +30.0% | +83.3% |
| Métrica | ABCL | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -289.0% | -38.6% | -250.4% |
| Net Margin | -194.9% | -33.6% | -161.3% |
| FCF Margin | -231.7% | -13.9% | -217.8% |
| ROE | -15.1% | -40.4% | +25.3% |
| ROA | -10.8% | -32.0% | +21.2% |
| Current Ratio | 11.32 | 2.84 | +8.48 |
| Debt / Equity | — | 0.28 | — |